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bjectives We hypothesized that patients most likely to beneﬁt would be those at high risk with a
horter duration of acute ischemia and who required transfer for percutaneous coronary interven-
ion (PCI).
ackground The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop
vents) study failed to demonstrate an improvement in the 90-day composite clinical end point of
arly treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or abciximab
lone.
ethods We performed a retrospective analysis of 2,452 patients in this double-blind, placebo-
ontrolled study. Patients were stratiﬁed by Thrombolysis In Myocardial Infarction (TIMI) risk score
or ST-segment elevation myocardial infarction (STEMI), presentation to a spoke (no PCI available) or
ub site, and symptom-to-randomization time. Outcomes included the primary composite end point
f death, ventricular ﬁbrillation after 48 h, cardiogenic shock, and congestive heart failure through
ay 90 as well as 1-year mortality.
esults Mortality for all patients at 1 year was directly related to TIMI risk score (23 of 1,223 
.9% in patients with score 3 and 145 of 1,229  11.8% with score 3, p  0.001). Patients
ith TIMI risk score 3 and presentation to a spoke site with a symptom-to-randomization time
4 h had signiﬁcantly better 1-year survival if treated with combination-facilitated PCI (hazard
atio [HR]: 0.351, p  0.01) as well as 90-day composite outcome (HR: 0.45, p  0.009). A trend
or improved survival was also observed in patients with TIMI score 3 and spoke site alone
HR: 0.549, p  0.06).
onclusions Facilitation of PCI with a combination of abciximab and half-dose reteplase im-
roved survival at 1 year in high-risk patients presenting to a spoke hospital with symptom-to-
andomization time 4 h. Further prospective study of facilitated PCI in this subgroup of pa-
ients is warranted. (J Am Coll Cardiol Intv 2009;2:917–24) © 2009 by the American College of
ardiology Foundation
rom the *Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; †Centocor Research & Development, Inc.,
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918rimary percutaneous coronary intervention (PCI) is more
ffective than thrombolytic therapy for the treatment of
T-segment elevation myocardial infarction (STEMI)
hen delivered by an experienced team soon after the onset
f symptoms (1). However, performance of PCI in a timely
ashion can be logistically challenging, and delays in time to
eperfusion with primary PCI adversely affect outcome (2).
his might become particularly important for patients who
equire transfer to another hospital where real world delays
ight greatly exceed those times observed in randomized
rials (3,4).
See page 931
For these reasons, the FINESSE (Facilitated Intervention
ith Enhanced Reperfusion Speed to Stop Events) study was
esigned to test the hypothesis that early pharmacologic
eperfusion before PCI could lead to myocardial salvage and
etter long-term outcomes. Although combination-facilitated
CI with abciximab plus half-dose reteplase improved early
ST-segment resolution compared
with abciximab alone (either early
or in the catheterization labora-
tory), there was no significant re-
duction in the primary composite
end point or 90-day mortality (5).
There were, however, trends to
potential benefit with a facilitated
strategy in patients with higher
risk, shorter symptom onset to
randomization time, and an inter-
mediate door-to-balloon time (5).
Therefore, we hypothesized that a
acilitated approach might benefit high-risk patients (defined
y Thrombolysis In Myocardial Infarction [TIMI] risk score)
ith a shorter duration of ischemia who also required transfer
or PCI. Our goal was to determine whether a subgroup of
atients could be identified at the time of presentation who
ould benefit from a facilitated PCI strategy.
ethods
he FINESSE study overview. The design of the FINESSE
tudy has been previously reported (5). In brief, this inter-
ational, double-blind, placebo-controlled trial randomized
,452 patients who presented within 6 h of the onset of
TEMI to receive 1 of 3 treatments: half-dose reteplase
lus abciximab (combination-facilitated PCI), abciximab
Herz-Zentrum bad Krozingen, Bad Krozingen, Germany; **Eli Lilly and Compan
alifornia; and the ‡‡Cleveland Clinic Foundation, Cleveland, Ohio. The FINESS
upported by Centocor, Inc., and Eli Lilly, Inc. Several of the authors (Drs. Lu, Effr
unding to participate in the trial. Dr. Herrmann did not receive research funding, and n
bbreviations
nd Acronyms
R  hazard ratio
I  myocardial infarction
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarction
IMI  Thrombolysis In
yocardial Infarctionanuscript received May 7, 2009; revised manuscript received June 3, 2009, accepted Junelone (abciximab-facilitated PCI), or placebo with abcix-
mab administered in the catheterization laboratory just
efore PCI (primary PCI). Patients in the combination-
acilitated PCI group received intravenous abciximab (0.25
g/kg) and reteplase (2 5-U boluses separated by 30 min for
hose younger than 75 years of age or 1 5-U bolus for those
5 years of age or older); patients in the abciximab-
acilitated group received an intravenous bolus of abciximab
0.25 mg/kg). All patients also received either low-
olecular-weight or unfractionated heparin and aspirin.
pproximately 60% of patients were enrolled at centers with
CI capability (hub sites), and the remainder were trans-
erred to PCI sites from “spoke” centers.
The primary study end point in the FINESSE study was
composite of all-cause mortality, ventricular fibrillation
ccurring 48 h after randomization, cardiogenic shock,
nd congestive heart failure requiring hospital stay or
mergency department visit within 90 days. Secondary end
oints included all-cause mortality at 90 days, ST-segment
esolution of more than 70% at 60 to 90 min after
andomization, and major or minor bleeding as assessed by
he TIMI classification.
tudy population. For this post hoc analysis, all 2,452
atients were initially included in the study population.
atients were then stratified by TIMI risk score for STEMI
6). The TIMI risk score for STEMI assigns points for age
2 points for ages 65 to 74 years, and 3 points for age 75
ears), diabetes or hypertension or angina (1 point), systolic
lood pressure 100 mm Hg (3 points), heart rate 100 (2
oints), Killip class II to IV (2 points), weight 67 kg (1
oint), anterior myocardial infarction (MI) or left bundle
ranch block (1 point), and time to treatment 4 h (1
oint) to create a score from 0 to 14 points. A correlation
etween TIMI risk score and 1-year mortality has con-
rmed its predictive value in STEMI patients undergoing
oth fibrinolysis and primary PCI (6,7).
In addition, we investigated 2 other supplementary terms:
) patients presenting to a spoke site that did not have PCI
apability, thus requiring transfer for primary PCI; and
) stratification by symptom-to-randomization time. Fi-
ally, the TIMI risk score was modified by not including the
time-to-treatment” variable, which assigns 1 point for
ime-to-treatment 4 h in order to include symptom-to-
andomization as a patient-related variable. Outcomes for
his analysis included the primary composite end point at 90
ays, 1-year mortality, and TIMI major or minor bleeding
hrough discharge or day 7, whichever was earlier.
ianapolis, Indiana; ††The Scripps Research Institute and Scripps Clinic, La Jolla,
cilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial was
d Barnathan) are employees of these companies. The other authors received research
itional funding was provided for this analysis.15, 2009.
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919tatistical analysis. Efficacy analyses were conducted on the
asis of the intention-to-treat principle, and safety analyses
ere performed according to the treatment received. Cox
roportional hazards model was used to investigate the
atient characteristics measured by modified TIMI STEMI
isk score; whether patients presented to a spoke site that
id not have PCI capability, thus requiring transfer for
rimary PCI; and symptom-to-randomization time and
heir relationship to both the composite 90-day primary end
oint and to 1-year mortality. Interaction p values between
reatment (combination-facilitated PCI vs. primary PCI)
nd any of these factors were used to guide the refinement
f the model to identify the subgroups with better survival
enefit by combination-facilitated PCI. Comparisons be-
ween the combination-facilitated PCI group and the
bciximab-facilitated PCI or primary PCI groups for par-
icular subgroups were performed with Cox model stratified
y the modified TIMI score with a significance level of 0.05.
aplan-Meier analyses were performed to estimate the rate
f mortality and primary composite end point over time by
reatment groups. No multiple comparison adjustment was
ade for any p value reported.
esults
aseline characteristics of the study population. We first
xplored the distribution of patients in the overall study
opulation by modified TIMI risk score (all components
xcept time to treatment4 h), which is shown in Figure 1A.
pproximately one-half of the patients had a TIMI risk score
3. Mortality at 1 year was directly related to TIMI risk score
Fig. 1B) at 1.9% for patients with a score 3 (23 of 1,223
atients) and 11.8% with score 3 (145 of 1,229 patients)
p  0.001). Outcomes for the 90-day composite end point
nd mortality to 1 year for each treatment arm with various
IMI risk score cutoffs are shown in Tables 1 and 2, respec-
ively. The choice of the dichotomous cut point of3 was data
riven and provided adequate sample size with a significantly
igher mortality with some evidence of treatment effect.
Among this higher-risk group, we next explored the
ubgroup of patients presenting to non-PCI (i.e., “spoke”)
ospitals, because in these centers, subjects were randomized
nd given study medications and then had a longer time until
CI could occur. These subjects again seemed to have a greater
reatment benefit from combination therapy (Table 2). Finally,
n the basis of the hypothesis that early reperfusion was most
ikely to have demonstrable effect in subjects with short acute
schemic times, we explored the additional effect of stratifying
he population by time from symptom onset to randomization
ime. Beyond 4 h, treatment effect seemed to fall off. Using 3 h
ave similar results with less power in the analysis due to
maller sample size. Therefore, we chose a subgroup consisting
f 397 patients (16%) with a TIMI risk score3, presentation
t a spoke site, and a symptom-to-randomization time4 h as ahigh-risk subset for analysis. Baseline characteristics of this
igh-risk subgroup in comparison with the entire FINESSE
tudy population are shown in Table 3.
Mortality through 1 year for each treatment group for the
ntire study and subgroups as outlined earlier are shown
Table 2, Fig. 2). There were no significant differences
etween treatment arms for 1-year mortality, either with
espect to all patients (Fig. 2A) or in those with TIMI score
3 (Fig. 2B), although the combination-facilitated PCI
roup demonstrated a trend to a lower mortality rate in
atients with a modified TIMI score 3 (10.1%) as com-
ared with the primary PCI group (12.5%) (hazard ratio
HR]: 0.78; 95% confidence interval: 0.52 to 1.17, p 
.231).
nﬂuence of site and time to randomization. Forty percent of
atients were enrolled at spoke sites without PCI capability.
he median door-to-balloon time was 120 min at hub sites
Figure 1. Number of Patients and 1-Year Mortality Stratified by Modified
TIMI Risk Score
(A) The distribution of patients in the overall study population by modiﬁed
Thrombolysis In Myocardial Infarction (TIMI) risk score (all components
except time to treatment 4 h are shown). Approximately one-half of the
patients had a modiﬁed TIMI risk score 3. Mortality at 1 year was directly
related to the modiﬁed TIMI risk score (B) at 1.9% for patients with a score
3 (23 of 1,223 patients) and 11.8% with score 3 (145 of 1,229 patients)
(p  0.001).nd 155 min at spoke sites, which included a median
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920ransfer time of 35 min (5). There was no significant
ifference between the incidence of the primary 90-day
omposite end point at spoke sites in combination-
acilitated (10.7%) and primary-PCI groups (12.0%, HR:
.88; 95% confidence interval: 0.56 to 1.39) (5). However, a
rend for benefit of combination-facilitated PCI was ob-
erved when TIMI risk score 3 was combined with
resentation at a spoke site (Table 2). In this subgroup of
atients, the 90-day end point was 21.5% in the primary
CI group compared with 14.7% in the combination-
acilitated PCI group (p  0.091); 1-year mortality was
5.2% and 9.0% in the primary-PCI and combination-
acilitated PCI groups, respectively (HR: 0.549, p  0.064)
Table 2, Fig. 2C).
The addition of a third stratification variable, time-to-
andomization, demonstrated further benefit with a facili-
ated approach (Table 2). After analyzing various symptom-
o-randomization cut points, a cutoff of4 h versus4 h was
elected to obtain the most significant interaction p value (p
Table 1. Outcomes for 90-Day Composite End Point for Subgroups With Va
Cutoffs
Combo-
Facilitated PCI
Abcixim
Facilitated
TIMI 2 67/555 (12.1) 76/550 (1
TIMI 3 59/414 (14.3) 67/415 (1
TIMI 4 51/270 (18.9) 51/276 (1
TIMI 5 33/145 (22.8) 35/140 (2
TIMI 3 and spoke 26/177 (14.7) 27/167 (1
TIMI 3 and spoke and time 2 h 7/57 (12.3) 8/67 (1
TIMI 3 and spoke and time 3 h 15/112 (13.4) 11/103 (1
TIMI 3 and spoke and time 4 h 18/137 (13.1) 19/135 (1
TIMI 3 and spoke and time 5 h 24/161 (14.9) 25/155 (1
Values are n/n (%) and hazard ratio (95% confidence interval). Comparison of various combinati
percutaneous coronary intervention (PCI) capability, and times from symptom onset to randomizat
CI confidence interval; Combo combination (half-dose reteplase plus abciximab).
Table 2. Outcomes for 1-Year Mortality for Subgroups With Various Combin
Cutoffs
Combo-
Facilitated PCI
Abcixima
Facilitated
TIMI 2 47/555 (8.5) 56/550 (1
TIMI 3 42/414 (10.1) 53/415 (1
TIMI 4 38/276 (13.8) 43/270 (1
TIMI 5 23/145 (15.9) 30/140 (2
TIMI 3 and spoke 16/177 (9.0) 24/167 (1
TIMI 3 and spoke and time 2 h 4/57 (7.0) 6/67 (9
TIMI 3 and spoke and time 3 h 9/112 (8.0) 13/103 (1
TIMI 3 and spoke and time 4 h 9/137 (6.6) 18/135 (1
TIMI 3 and spoke and time 5 h 13/161 (8.1) 21/155 (1
Values are n/n (%) and hazard ratio (95% confidence interval). Comparison of various combinations
to randomization on the 1-year mortality in all 3 treatment arms.Abbreviations as in Table 1..044) between symptom-to-randomization time and treat-
ent group (combination-facilitated PCI vs. primary PCI).
atients with a modified TIMI risk score of3 who presented
o a spoke site and had a symptom-to-randomization time4
did significantly better as measured by the primary composite
utcome in both facilitated groups compared with primary
CI (combination-facilitated PCI, HR: 0.45, p  0.009;
bciximab-facilitated PCI, HR: 0.53, p 0.035) (Table 1, Fig.
). One-year mortality in this subgroup was only significantly
educed for the combination-facilitated PCI group (HR: 0.35,
 0.01) (Fig. 2D).
afety. Bleeding was assessed with the TIMI classification
hrough discharge or day 7, whichever occurred sooner. In the
verall study, nonintracranial TIMI major or minor bleeding
ccurred in 14.5%, 10.1%, and 6.9% of patients in the
ombination-facilitated PCI, abciximab-facilitated PCI, and
rimary-PCI groups, respectively (p  0.001 for the compar-
son of combination with primary PCI) (5). In the subgroup of
atients with modified TIMI risk score 3, spoke site, and
Combinations of Cutoffs
Primary PCI Combo vs. Primary
Abciximab vs.
Primary
77/546 (14.1) 0.814 (0.586–1.130) 0.921 (0.671–1.265)
70/400 (17.5) 0.776 (0.548–1.098) 0.874 (0.625–1.223)
53/259 (20.5) 0.871 (0.592–1.280) 0.869 (0.591–1.277)
32/126 (25.4) 0.892 (0.548–1.453) 0.949 (0.588–1.534)
34/158 (21.5) 0.606 (0.363–1.012) 0.681 (0.410–1.131)
10/53 (18.9) 0.810 (0.299–2.191) 0.872 (0.328–2.320)
26/103 (25.2) 0.429 (0.224–0.821) 0.378 (0.186–0.770)
29/125 (23.2) 0.453 (0.249–0.824) 0.531 (0.296–0.955)
31/139 (22.3) 0.586 (0.342–1.004) 0.654 (0.384–1.113)
utoffs for Thrombolysis In Myocardial Infarction (TIMI) risk, presentation at a spoke site without
he 90-day composite end point in all 3 treatment arms.
s of Cutoffs
Mortality at 1 Year
Primary PCI Combo vs. Primary
Abciximab vs.
Primary
54/546 (9.9) 0.815 (0.551–1.206) 0.998 (0.687–1.451)
50/400 (12.5) 0.778 (0.516–1.173) 1.009 (0.686–1.486)
37/259 (14.3) 0.938 (0.596–1.477) 1.108 (0.714–1.720)
26/126 (20.6) 0.760 (0.433–1.333) 1.059 (0.626–1.791)
24/158 (15.2) 0.549 (0.291–1.036) 0.924 (0.524–1.632)
8/53 (15.1) 0.591 (0.175–2.003) 0.957 (0.314–2.914)
18/103 (17.5) 0.410 (0.182–0.922) 0.725 (0.353–1.490)
20/125 (16.0) 0.351 (0.159–0.777) 0.824 (0.432–1.573)
20/139 (14.4) 0.515 (0.255–1.040) 0.921 (0.497–1.709)
ffs for TIMI risk, presentation at a spoke site without PCI capability, and times from symptom onsetrious
ab-
PCI
3.8)
6.1)
8.5)
5.0)
6.2)
1.9)
0.7)
4.1)
6.1)
ons of c
ion on tation
b-
PCI
0.2)
2.8)
5.9)
1.4)
4.4)
.0)
2.6)
3.3)
3.5)
of cuto
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4 h (n  397). PCI  percutaneous coronary intervention.
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921ymptom-to-randomization time 4 h, the rates of nonintra-
ranial TIMI major or minor bleeding occurred in 15.3%,
1.9%, and 10.4% for the same 3 treatment groups, respec-
ively. Compared with primary PCI, the bleeding rate was
imilar for abciximab-facilitation (p  0.85) and trended
igher with combination therapy (p  0.32) (Table 4).
hrombocytopenia, in this subgroup, was higher in the
bciximab-facilitated group compared with the other treat-
ent groups (Table 4), although this was not observed in the
rial overall (5).
iscussion
mproving outcomes with pharmacologic therapy for the
reatment of acute MI before planned primary PCI in order
o combine the benefits of early drug reperfusion with later
nd more complete mechanical reperfusion has great theo-
etic appeal (8). Despite the absence of benefit with a
acilitated PCI strategy in the FINESSE study, we retro-
pectively sought to determine whether a subset of patients
ould be indentified upon presentation that would be more
ikely to benefit. In this study we demonstrated that, in a
ubgroup of 397 high-risk patients presenting to non-PCI
ospitals within 4 h of symptom onset, combination-
acilitated PCI reduced 1-year mortality compared with
rimary PCI.
revious studies. Early studies exploring the facilitated PCI
oncept focused on determining whether an invasive strat-
gy and the timing of such a strategy could demonstrate an
mprovement over a conservative strategy after the admin-
stration of a thrombolytic agent. (9). No benefit was
emonstrated, but these trials were performed in advance of
Table 3. Comparison of Variables Between the Overall Trial Population
and the Study Subgroup
All Patients Study Population
n (%) 2,452 (100) 397 (16)
Female 642 (26.2) 154 (38.8)
Age 75 yrs 388 (15.8) 142 (35.8)
Previous MI 266 (10.8) 46 (11.6)
Diabetes 380 (15.5) 89 (22.4)
Anterior infarction 1,173 (47.8) 209 (52.6)
Killip class II–IV 241 (9.8) 71 (17.9)
Symptom-to-randomization time, h
2 787 (32.1) 177 (44.6)
2–4 1,101 (44.9) 220 (55.4)
4 564 (23.0) 0 (0.0)
Randomization-to-balloon time 1 h 251 (10.2) 1 (0.3)
Modiﬁed TIMI risk score 3 1,229 (50.1) 397 (100)
Spoke site 984 (40.1) 397 (100)
Values are n (%).
MImyocardial infarction; TIMI Thrombolysis In Myocardial Infarction.he availability of stents and before the routine use ofFigure 2. 1-Year Mortality in the FINESSE Study and Subgroups for Each
Treatment Arm
Estimates of mortality at 1-year are shown for each treatment group in: (A) all
patients (n  2,452); (B) patients with a modiﬁed Thrombolysis In Myocardial
Infarction (TIMI) risk score 3 (n  1,229); (C) patients with a modiﬁed TIMI
risk score 3 and spoke site randomization (n  502); and (D) patients with a
modiﬁed TIMI risk score 3, spoke site, and symptom-to-randomization time
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922lycoprotein IIb/IIIa inhibitors and thienopyridines (1).
everal recent trials have suggested benefit for early PCI
ith stenting after thrombolysis (SIAM-III [Southwest
erman Interventional Study in Acute Myocardial Infarc-
ion], GRACIA-1 [Grupo de Analisis de la Cardiopatia
squemica Aguda], CAPITAL-AMI [Combined Angio-
lasty and Pharmacological Intervention versus Thrombol-
sis Alone in Acute Myocardial Infarction]), but these
tudies were limited, because they were open-label and had
mall sample sizes (9).
The ASSENT-4 PCI (Assessment of the Safety and
fficacy of a New Treatment Strategy with PCI) trial was a
arger randomized contemporary trial of full-dose tenect-
plase before PCI (10). This trial was discontinued early,
ue to worse outcomes in the facilitated PCI arm, despite
igher TIMI flow grade 3 before PCI in the tenecteplase
rm. The rapid drug-to-balloon time and lack of adequate
ntiplatelet therapy before PCI might have contributed to
he worse outcomes observed.
In the CARESS (Combined Abciximab RE-teplase
tent Study) in acute MI trial, 600 high-risk patients
eceiving half-dose reteplase and abciximab were random-
zed to PCI versus conservative care. The composite end
oint of death, MI, and refractory ischemia at 30 days was
educed from 10.4% to 4.4% with early PCI (11). In the
RANSFER-AMI (Trial of Routine Angioplasty and
tenting after Fibrinolysis to Enhance Reperfusion in Acute
Figure 3. Primary End Point in High-Risk Subgroup for Each
Treatment Arm
The primary composite end point (all-cause mortality, ventricular ﬁbrillation
occurring 48 h after randomization, cardiogenic shock, and congestive
heart failure requiring hospital stay or emergency department visit within
90 days) is shown by treatment group for the subgroup of patients with
modiﬁed TIMI risk score 3, spoke site, and symptom-to-randomization
time 4 h. Abbreviations as in Figure 2.I), urgent transfer for PCI after fibrinolysis was associatedith a reduction in reinfarction and the 30-day composite of
eath, MI, and recurrent ischemia (12). In this study, all
atients received a loading dose of clopidogrel, and 73%
eceived glycoprotein IIb/IIIa inhibitors during PCI.
Several trials have examined the use of glycoprotein
Ib/IIIa inhibition without fibrinolysis administered early to
cute MI patients after the first demonstration of benefit in
randomized trial with abciximab (13). Similarly, in an
bservational registry of 1,066 higher-risk patients who
eceived abciximab before transfer for primary PCI, 30-day
ortality was reduced by 50% (14). However, in a random-
zed study of tirofiban, no improvement occurred in either
IMI flow or perfusion, possibly due to inadequate dosing,
oo short a time between drug administration and angiog-
aphy, or the lack of high-risk patients (15).
Finally, a single center observational analysis of facilitated
CI was recently published (16). In 786 patients treated at
community hospital with a glycoprotein IIb/IIIa inhibitor
nd/or intravenous fibrinolytic before transfer for PCI with
door-to-balloon time between 90 and 150 min, 50% fewer
ajor adverse clinical events were observed as compared
ith 767 patients undergoing primary PCI at the tertiary
enter despite a longer door-to-balloon time (16).
ationale and results of the present investigation. In the
INESSE trial, neither facilitation of PCI with half-dose
eteplase plus abciximab nor facilitation with abciximab
lone significantly improved clinical outcomes, as compared
ith abciximab given at the time of PCI (5). However, the
enefits of PCI are time-related (17) and lost more quickly
n higher-risk patients (18). A reperfusion strategy should
e selected not only on the basis of the benefits and
Table 4. Comparison of TIMI Major and Minor Bleeding in the
3 Treatment Arms in the Study Population
Primary PCI
(n  125)
Abciximab-
Facilitated PCI
(n  135)
Combination-
Facilitated PCI
(n  137)
Nonintracranial major or
minor TIMI
13 (10.4) 16 (11.9) 21 (15.3)
TIMI major (including ICH) 3 (2.4) 8 (5.9) 7 (5.1)
Stroke
ICH 0 0 0
Ischemic 3 (2.4) 1 (0.7) 2 (1.5)
Transfusion
pRBC 4 (3.2) 6 (4.4) 11 (8.0)
Platelets 0 2 (1.5) 0
Thrombocytopenia
100k 3 (2.4) 10 (7.4) 3 (2.2)
50k 1 (0.8) 6 (4.4) 2 (1.5)
20k 0 3 (2.2) 0
Values are n (%).
ICH intracranial hemorrhage; PCIpercutaneous coronary intervention; pRBCpacked redblood cell; TIMI Thrombolysis In Myocardial Infarction.
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923imitations of the reperfusion strategy and time delays (both
resentation delay and PCI-related delay) but also patient
haracteristics.
We hypothesized that the patients most likely to benefit
rom a facilitated strategy would be those at high risk with
shorter duration of ischemia who required transfer for
CI. To make an analysis of such patients clinically useful,
e focused on information that would be readily available at
atient’s presentation. In this regard, the TIMI risk score
or STEMI is easily calculated and has been validated in
atients treated with fibrinolysis and primary PCI (6,7).
ecause patients with very short door-to-balloon times are
nlikely to benefit from pharmacologic reperfusion before
CI, we limited our analysis to patients presenting at a
poke site requiring transfer for PCI. Finally, because
brinolysis is more effective in less mature thrombotic
esions (19), we included only patients with a symptom-to-
andomization time 4 h.
The benefit we observed in 90-day composite outcome
nd 1-year mortality in the high-risk group treated with a
acilitated approach was associated with a trend to greater
leeding (Table 4). However, nonintracranial TIMI major
nd minor bleeding were not significantly different in this
igh-risk subgroup as compared with the overall study
opulation but trended higher in the primary PCI group
10.4% in our subgroup vs. 6.9% in the overall study
opulation). This might reflect the high-risk characteristics
f these patients or be related to chance variation in a small
ubgroup of patients.
tudy limitations. This is a retrospective, post-hoc analysis
f a randomized trial. Therefore, our conclusions are ex-
loratory and require validation in a prospective randomized
rial. We are hopeful that future trials of facilitation for PCI
n acute MI will consider inclusion of the subset of patients
e have identified as a pre-planned analysis. The lack of
re-specified clopidogrel administration is an additional
tudy limitation.
The TIMI risk score was modified to exclude the “time-
o-treatment” variable in order to allow inclusion of time-
o-treatment as a patient-related variable. Therefore, previ-
us studies of the predictive value of the unmodified TIMI
isk score might not be directly comparable. We also
xamined higher cut points for TIMI risk, which revealed a
imilar effect on 1-year mortality (e.g., 1.9% for score5 vs.
8.3% for score 5) but reduced the overall number of
atients available and the statistical power for analysis.
imilarly, using a shorter symptom-to-randomization time
e.g., 3 h) resulted in a similar benefit for 1-year mortality
ith combination therapy (HR: 0.41, p 0.03) but reduced
ower for analysis (Table 1). Future prospective analyses of
his subgroup will need to test various TIMI risk scores and
ime points.onclusions
n a subgroup of patients in the FINESSE trial identified as
igh risk on the basis of a modified TIMI risk score 3,
resentation to a spoke site without PCI capability, and with a
ymptom-to-randomization time 4 h, facilitation of PCI
ith early administration of a combination of abciximab and
alf-dose reteplase or abciximab alone may reduce 90-day
linical outcomes compared with abciximab given just before
CI. Furthermore, combination-facilitated PCI significantly
educed 1-year mortality as compared with primary PCI. We
elieve that further prospective evaluation of this high-risk
ubgroup of acute MI patients is warranted.
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